Trial NCT03769181

View at ClinicalTrials.gov 
Org. Study IDs: ACT15320
Secondary IDs: 2018-002442-37 U1111-1211-9010

Last trial update was posted on 2023-10-17

MeSH Interventions

Cemiplimab

MeSH Conditions

Lymphoma

Other Conditions


Stopping Reasons

Study was stopped after interim analysis for all 4 cohorts with results either not fulfilling the pre-planned interim analysis criteria or fulfilling the criteria but as per sponsor decision. It was not due to any safety concern

Limitations And Caveats

The efficacy results observed in Cohorts B and C did not fulfill the pre-planned interim analysis criteria allowing the study to move to Phase 2 Stage 2 in these cohorts. The efficacy results observed in Cohort A1 and A2 fulfilled the pre-planned interim analysis criteria in Stage 1 to move to Phase 2 Stage 2 in these cohorts. However, the study was stopped for all the cohorts as per Sponsor's decision.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID